RESULTS Meta- analysis suggested that statin therapy is associated with a significant elevation of PON1 paraoxonase and arylesterase activities , but not PON1 protein concentration .
The PON1-enhancing effects of statins were robust in the sensitivity analyses and were independent of statin dose , treatment duration and changes in plasma low-density lipoprotein cholesterol concentration .
CONCLUSION The increase of paraoxonase and arylesterase activities with statins is a pleiotropic lipid-independent clinical benefit that may partly explain the putative effects of statins in preventing cardiovascular outcomes
BACKGROUND Decreased activity of the enzyme paraoxonase-1 ( PON1 ) has been demonstrated in cardiovascular diseases .
Statins , the forefront of pharmacotherapy for dyslipidemia , have been shown to enhance PON1 activity but clinical findings have not been conclusive .
OBJECTIVE To systematic ally review the clinical findings on the impact of statin therapy on PON1 status ( protein concentrations and activities of paraoxonase and arylesterase ) and calculate an effect size for the mentioned effects through meta- analysis of available data .
Antioxidant effect of atorvastatin is independent of PON1 gene T(–107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients
ABSTRACT Background : Serum paraoxonase ( PON1 ) , a high density lipoprotein (HDL)-bound antioxidant enzyme , plays a role in atherosclerosis . An increase in PON1 activity has been reported following statin treatment . Objective : In the present study the following factors were evaluated : the influence of PON1 gene Q192R , L55 M and T(–107)C polymorphisms on the response of LDL oxidisability and PON1 activity to atorvastatin treatment . Research design and methods : 205 Sicilian subjects with primary hypercholesterolaemia ( HCh ) and 69 healthy subjects as controls were concurrently enrolled . Hypercholesterolaemic patients were r and omly divided into two groups : an atorvastatin group ( 10 mg/day atorvastatin ) and a placebo group .  Lipid profile , markers of LDL resistance to in vitro oxidation ( lag-phase , oxidation rate and thiobarbituric acid-reactive substances ) , vitamin E content in LDL , PON1 activity and genotypes in both HCh and control subjects were determined at baseline . The same parameters were measured again after 3 weeks of treatment in both the atorvastatin and placebo groups . Results : HCh subjects showed significantly lower LDL resistance to oxidation , vitamin E content and PON1 activity levels than controls . A strong association was found among PON1 T(–107)C genotypes , LDL susceptibility to oxidation , vitamin E content and PON1 activity . After treatment , the atorvastatin group displayed a significant decrease in total cholesterol , LDL-cholesterol levels , and LDL susceptibility to oxidation , and an increase in vitamin E content and PON1 activity , compared with baseline values . Unlike PON1 activity levels , no difference among PON1 gene polymorphisms and reduction in markers of LDL oxidisability was observed . Conclusions : These results show , for the first time , that atorvastatin is able to improve the resistance to LDL oxidation independently of PON1 gene polymorphism
RESULTS Meta- analysis suggested that statin therapy is associated with a significant elevation of PON1 paraoxonase and arylesterase activities , but not PON1 protein concentration .
The PON1-enhancing effects of statins were robust in the sensitivity analyses and were independent of statin dose , treatment duration and changes in plasma low-density lipoprotein cholesterol concentration .
CONCLUSION The increase of paraoxonase and arylesterase activities with statins is a pleiotropic lipid-independent clinical benefit that may partly explain the putative effects of statins in preventing cardiovascular outcomes
BACKGROUND Decreased activity of the enzyme paraoxonase-1 ( PON1 ) has been demonstrated in cardiovascular diseases .
Statins , the forefront of pharmacotherapy for dyslipidemia , have been shown to enhance PON1 activity but clinical findings have not been conclusive .
OBJECTIVE To systematic ally review the clinical findings on the impact of statin therapy on PON1 status ( protein concentrations and activities of paraoxonase and arylesterase ) and calculate an effect size for the mentioned effects through meta- analysis of available data .